Brad Whitchurch
Founder, CEO and Chairman
7 on 7+ Score
Executive Takeaway
Seal Shield's site carries strong proof. Mayo Clinic, Cleveland Clinic and Johns Hopkins sit among its client logos, an Industries menu sorts visitors by field, and a newsletter sign-up keeps people in touch. What the site doesn't show yet is people. The About page lists benefits but no faces, the homepage video shows products being washed, and the blog posts carry no dates. Clean Talk, with 84 episodes of conversations with infection-control experts, ties the company to the wider conversation in its field, and the podcast feed has been quiet since February 2024. The website scores 20 of 49, where a typical Vistage room averages 13 to 14, and the IDEA score is 21.
Seven criteria, each scored 1 to 7 by Alan Power and Gair Maxwell. The sum is your website score out of 49. Vistage room average: 13 to 14. A score above 20 is strong.
How You Show Up in the World
The IDEA Score measures what happens before someone reaches your website, the off-site signal that shapes perception from the first search, the LinkedIn scroll, the founder post.
The Idea That Changes Everything
Seven axes. Each one measures a different dimension of how your off-site signal lands, not what your website says, but what the world hears before anyone clicks.
Pull vs. push. Category of one vs. category of many. A founder voice vs. a corporate signal. These are the levers that determine whether a prospect arrives already interested, or arrives already skeptical.
Where You Can Show Up Next
How to Build Your Legend
Short Term
Medium Term
Who's Setting the Pace
The Industry Around You
Infection control is a growing market, and hospitals report their infection rates to the CDC every year. That keeps the topic in front of the executives who buy.
What Keeps You Up at Night
The forces shaping Seal Shield's competitive environment, and why standing still is not an option.
Seal Shield, Man & Machine and Xenex all lead with medical-grade or pathogen claims. A buyer comparing sites reads the same words more than once.
HeadwindCleanbox publishes prices, an ROI calculator and a whitepaper. Xenex shows six customer testimonials with names. Buyers are learning to expect that kind of evidence.
HeadwindEvery year the CDC reports CLABSI, CAUTI, surgical site infections, MRSA and C. difficile by hospital and by state. Buyers come in knowing their numbers, and they want suppliers who can talk about them.
HeadwindWhere the Opportunity Lives
The same forces creating pressure are also creating openings for those willing to lead.
From 2023 to 2024, hospital-onset C. difficile fell 11%, CAUTI 10%, CLABSI 9% and MRSA bacteremia 7%. Infection preventionists have momentum, and they're looking for partners who can help them keep it.
CDC National and State HAI Progress Report, 2024 TailwindInfection control is expected to reach $77.67 billion by 2030. More money is coming into the field, and buyers will have more options to choose from.
MarketsandMarkets, 2025 TailwindSeal Shield exhibits at the Synova Perinatal Leadership Forum on November 9 and 10, after HIMSS26 and IPAC Canada. Each event is a chance to record a Clean Talk conversation.
Seal Shield on X, November 2026 TailwindYour Future-State Brand Expression
The full roadmap answers who Seal Shield is beyond its products, builds the pieces that show it, and sets up the routine that keeps it going. It moves through Clarify, Identity and Growth, toward Legend.